acetaldehyde has been researched along with Atherosclerosis in 10 studies
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.
acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.
aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxidized epitopes such as malondialdehyde-acetaldehyde (MAA) play a crucial role in the progression of atherosclerosis through activation of the humoral immune response." | 8.12 | Salivary IgA antibody to malondialdehyde-acetaldehyde associates with mild periodontal pocket depth. ( Akhi, R; Buhlin, K; Hörkkö, S; Kyrklund, M; Mäntylä, P; Nissinen, AE; Paju, S; Pussinen, PJ; Sinisalo, J; Wang, C, 2022) |
| "Antibodies to malondialdehyde (MDA)-modified macromolecules (adducts) have been detected in the serum of patients with atherosclerosis and correlate with the progression of this disease." | 7.76 | Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. ( Anderson, DR; Duryee, MJ; Garvin, RP; Hunter, CD; Klassen, LW; Schaffert, CS; Thiele, GM; Tuma, DJ, 2010) |
| "Oxidized epitopes such as malondialdehyde-acetaldehyde (MAA) play a crucial role in the progression of atherosclerosis through activation of the humoral immune response." | 4.12 | Salivary IgA antibody to malondialdehyde-acetaldehyde associates with mild periodontal pocket depth. ( Akhi, R; Buhlin, K; Hörkkö, S; Kyrklund, M; Mäntylä, P; Nissinen, AE; Paju, S; Pussinen, PJ; Sinisalo, J; Wang, C, 2022) |
| "Antibodies to malondialdehyde (MDA)-modified macromolecules (adducts) have been detected in the serum of patients with atherosclerosis and correlate with the progression of this disease." | 3.76 | Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. ( Anderson, DR; Duryee, MJ; Garvin, RP; Hunter, CD; Klassen, LW; Schaffert, CS; Thiele, GM; Tuma, DJ, 2010) |
| "Inflammation is widely accepted to play a major role in atherosclerosis and other cardiovascular diseases." | 2.52 | Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease. ( Anderson, DR; Antoniak, DT; Duryee, MJ; Mikuls, TR; Thiele, GM, 2015) |
| "Inflammation is known to induce oxidative stress, which can lead to lipid peroxidation." | 1.62 | Malondialdehyde-Acetaldehyde Modified (MAA) Proteins Differentially Effect the Inflammatory Response in Macrophage, Endothelial Cells and Animal Models of Cardiovascular Disease. ( Anderson, DR; Clemens, DL; Duryee, LM; Duryee, MJ; Garvin, RP; Opperman, PJ; Thiele, GM, 2021) |
| "Treatment of periodontitis has beneficial effects on systemic inflammation markers that relate to progression of atherosclerosis." | 1.48 | Immunization with gingipain A hemagglutinin domain of Porphyromonas gingivalis induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein. ( Akhi, R; Hörkkö, S; Kankaanpää, J; Kummu, O; Kyrklund, M; Nissinen, A; Pussinen, P; Turunen, SP; Wang, C, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duryee, MJ | 4 |
| Clemens, DL | 1 |
| Opperman, PJ | 1 |
| Thiele, GM | 4 |
| Duryee, LM | 1 |
| Garvin, RP | 2 |
| Anderson, DR | 4 |
| Lomzenski, HE | 1 |
| Chen, SC | 1 |
| Ye, F | 1 |
| Mikuls, TR | 2 |
| Ormseth, MJ | 1 |
| Akhi, R | 2 |
| Nissinen, AE | 1 |
| Wang, C | 3 |
| Kyrklund, M | 2 |
| Paju, S | 1 |
| Mäntylä, P | 1 |
| Buhlin, K | 1 |
| Sinisalo, J | 1 |
| Pussinen, PJ | 1 |
| Hörkkö, S | 4 |
| Kummu, O | 3 |
| Kankaanpää, J | 1 |
| Nissinen, A | 2 |
| Turunen, SP | 3 |
| Pussinen, P | 1 |
| Tawakol, A | 1 |
| Jaffer, F | 1 |
| Ma, S | 1 |
| Cao, F | 1 |
| Prus, P | 1 |
| Lehtimäki, J | 1 |
| Veneskoski, M | 2 |
| Antoniak, DT | 1 |
| Klassen, LW | 1 |
| Schaffert, CS | 1 |
| Tuma, DJ | 1 |
| Hunter, CD | 1 |
| Rannikko, S | 1 |
| Levonen, AL | 1 |
2 reviews available for acetaldehyde and Atherosclerosis
| Article | Year |
|---|---|
Targeting ALDH2 in Atherosclerosis: Molecular Mechanisms and Therapeutic Opportunities.
Topics: Acetaldehyde; Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Atherosclerosis; Humans | 2019 |
Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease.
Topics: Acetaldehyde; Atherosclerosis; Humans; Inflammation; Malondialdehyde | 2015 |
8 other studies available for acetaldehyde and Atherosclerosis
| Article | Year |
|---|---|
Malondialdehyde-Acetaldehyde Modified (MAA) Proteins Differentially Effect the Inflammatory Response in Macrophage, Endothelial Cells and Animal Models of Cardiovascular Disease.
Topics: Acetaldehyde; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Adhesion Molecules; Cells, Cul | 2021 |
Serum anti-malondialdehyde-acetaldehyde IgA antibody concentration improves prediction of coronary atherosclerosis beyond traditional risk factors in patients with rheumatoid arthritis.
Topics: Acetaldehyde; Arthritis, Rheumatoid; Atherosclerosis; Autoantibodies; C-Reactive Protein; Coronary A | 2022 |
Salivary IgA antibody to malondialdehyde-acetaldehyde associates with mild periodontal pocket depth.
Topics: Acetaldehyde; Aggregatibacter actinomycetemcomitans; Antigens, Bacterial; Atherosclerosis; Chaperoni | 2022 |
Immunization with gingipain A hemagglutinin domain of Porphyromonas gingivalis induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein.
Topics: Acetaldehyde; Adhesins, Bacterial; Animals; Antibodies, Bacterial; Atherosclerosis; Bacterial Protei | 2018 |
Imaging the Intersection of Oxidative Stress, Lipids, and Inflammation: Progress Toward Personalized Care of Atherosclerosis.
Topics: Acetaldehyde; Atherosclerosis; Epitopes; Humans; Inflammation; Lipids; Magnetic Resonance Imaging; M | 2018 |
Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts.
Topics: Acetaldehyde; Animals; Antibodies, Monoclonal; Apoptosis; Atherosclerosis; Autoantibodies; Binding, | 2014 |
Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis.
Topics: Acetaldehyde; Animals; Aorta; Atherosclerosis; Dihydropyridines; Epitopes; Male; Malondialdehyde; Mi | 2010 |
Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a.
Topics: Acetaldehyde; Anaphylatoxins; Animals; Antibodies, Blocking; Apoptosis; Atherosclerosis; Cattle; Cel | 2011 |